<span id="midArticle_start"/> Biotechnology company Neurocrine Biosciences Inc said it had suspended two planned clinical trials of its experimental drug to treat a potentially life-threatening genetic disorder called congenital adrenal hyperplasia.
<span id="midArticle_0"/>The company's shares fell as much as 14.7 percent to $38.63 in after-market trading on Monday. The stock had touched a nine-year high of $45.98 during regular trading hours.
<span id="midArticle_1"/>Neurocrine suspended the trials of the drug, NBI-77860, citing certain preclinical findings that had not been observed in previous animal studies.
<span id="midArticle_2"/> <span class="first-article-divide"/>The U.S. Food and Drug Administration has informed Neurocrine that the drug's development program would be placed on partial clinical hold, the company said.
<span id="midArticle_3"/> <span class="second-article-divide"/>The company said it would continue working with the FDA to decide the next step for the drug.
<span id="midArticle_4"/> <span class="third-article-divide"/>
<span id="midArticle_5"/> (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Simon Jennings)
<span id="midArticle_6"/>
<span id="midArticle_0"/>The company's shares fell as much as 14.7 percent to $38.63 in after-market trading on Monday. The stock had touched a nine-year high of $45.98 during regular trading hours.
<span id="midArticle_1"/>Neurocrine suspended the trials of the drug, NBI-77860, citing certain preclinical findings that had not been observed in previous animal studies.
<span id="midArticle_2"/> <span class="first-article-divide"/>The U.S. Food and Drug Administration has informed Neurocrine that the drug's development program would be placed on partial clinical hold, the company said.
<span id="midArticle_3"/> <span class="second-article-divide"/>The company said it would continue working with the FDA to decide the next step for the drug.
<span id="midArticle_4"/> <span class="third-article-divide"/>
<span id="midArticle_5"/> (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Simon Jennings)
<span id="midArticle_6"/>
via Smart Health Shop Forum http://ift.tt/1Qjpg0Q
No comments:
Post a Comment